Syncope Trial to Understand Tilt Testing Early or Recorders Study (STUTTER)

May 9, 2023 updated by: University of Alberta
Pragmatic research study to determine which of the two standard syncope therapies yields a faster path to diagnosis- head up tilt (HUT) table or implantable loop recorder (ILR).

Study Overview

Detailed Description

RESEARCH QUESTION: In syncope patients at least 50 years of age, a strategy of first conducting a tilt table (HUT) will provide an earlier diagnosis at less cost than a strategy of first implanting an implantable loop recorder (ILR).

BACKGROUND: Syncope is a common condition. Approximately 0.6%- 1.5% of all Emergency Department (ED) visits occurs for syncope and of these, anywhere from 12%-83% are admitted, depending on the country. The incidence rates for acute care visits increases with age and rises steeply after the age of 50 years. Approximately one third of patients have at least one recurrence of syncope in 3 years of follow-up. A recent analysis from Alberta found the total cost of syncope presentations to the ED was $530 million dollars over a 6-year period. Syncope has numerous causes, ranging from benign to life threatening, and determining the underlying etiology is often challenging. Reflex syncope (vasovagal) is the most frequent cause of syncope in all age groups and clinical settings. However, arrhythmic causes, with higher clinical risk, become more common in older patients, and are responsible for about 10% of syncope visits to the ED. The current approach for investigation of patients with unexplained syncope is usually unstructured, with multiple specialist evaluations, numerous and expensive tests, and recurring acute care visits. This results in high and unnecessary costs. There are three competing approaches to diagnosis: a structured history, head-up tilt (HUT) test, and implantable loop recorders (ILR).

Often syncope can be diagnosed on the basis of history, physical examination, and electrocardiogram (ECG). However, even after this initial evaluation, syncope may remain unexplained, accounting for as many as 41% of cases in older patients. In older patients, history is often less reliable, due to a lack of autonomic symptoms associated with vasovagal syncope, amnesia for pre-syncopal symptoms, and lack of witnesses. Further, co-morbidities and polypharmacy add complexity to the diagnostic process. HUT: The HUT test has been used to evaluate patients with syncope for nearly 3 decades. It is an orthostatic stress test to assess the susceptibility of a vasovagal response to a postural change from a supine to an upright position. A positive response is defined as inducible presyncope or syncope associated with hypotension, with or without bradycardia (including asystole) that reproduces clinical symptoms. HUT has been used in patients with suspected vasovagal syncope, when the history is unhelpful. Although enthusiasm has waned for the role of HUT in the evaluation of syncope due to variable protocols leading to high heterogeneity of test outcomes, false-positives in controls, and availability of long-term cardiac monitoring; there is good evidence for its usefulness.

ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.

Early observational and case-control studies found that the ILR leads to earlier diagnosis and reduced the rate of unexplained syncope compared to HUT. Despite ILR entering routine clinic practice over the last 25 years, there are surprisingly few rigorous data of its use in the management of unexplained syncope. Comparisons of strategies of HUT and ILR: Two randomized controlled studies have reported on the diagnostic yield of an early ILR strategy compared to conventional testing including HUT in older patients with unexplained syncope. All reported an increased diagnostic accuracy with ILR and a lower cost per diagnosis, but each has substantial limitations. Study Structure: This will be a formal pragmatic study of 2 diagnostic strategies, designed around the PRECIS2 criteria addressing which test should be done first, and subsequent care will be left in the hands of the physician responsible for assessing syncope. Settings: Patients will be recruited from the ED, general cardiology, arrhythmia, and syncope clinics, and medical and cardiology wards.

Randomization: Patients will be randomized to either i) the early HUT [protocol:

supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes] OR ii) early implant of ILR without hospital admission.

Regardless of the outcome, subsequent testing and care will be in the hands of the responsible physician. Patients will be seen 1 week after ILR implantation for wound assessment and to reinforce patient understanding of the activation process. Subsequent 3-year follow-up will occur according to the policies of the device clinic (usually every 6 months). Patients will be seen quickly after a symptomatic event.

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Alberta
      • Calgary, Alberta, Canada, T2N 4N1
        • Recruiting
        • University of Calgary
        • Contact:
      • Edmonton, Alberta, Canada, T6G 2B7
        • Recruiting
        • University of Alberta
        • Contact:
          • Xenia Cravetchi, MSc
          • Phone Number: 7804078594

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

48 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 50 years old
  • syncope (defined in 2017 ACC/AHA/HRS guidelines[16]) in the prior 12 months
  • diagnosis unclear after history, physical exam andelectrocardiogram
  • no apparent risk of death due to the cause of syncope.

Exclusion Criteria:

  • inability to give informed consent
  • unable to attend routine follow up in device clinic
  • positive carotid sinus massage.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: All eligible participants
All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies.

Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.

the early HUT [protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes]

ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to diagnosis
Time Frame: 1 year
the proportion of patients with a definite diagnosis by 1 year.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 28, 2019

Primary Completion (Anticipated)

December 31, 2024

Study Completion (Anticipated)

December 31, 2024

Study Registration Dates

First Submitted

June 2, 2019

First Submitted That Met QC Criteria

June 2, 2019

First Posted (Actual)

June 4, 2019

Study Record Updates

Last Update Posted (Estimate)

May 11, 2023

Last Update Submitted That Met QC Criteria

May 9, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Syncope

Clinical Trials on Head Up Tilt Table (HUT)

3
Subscribe